MG
Therapeutic Areas
Dianthus Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DNTH103 | Generalized Myasthenia Gravis (gMG) | Phase 1 |
| Next-generation complement inhibitors | Undisclosed autoimmune indications | Discovery |
| Drug | Indication | Phase |
|---|---|---|
| DNTH103 | Generalized Myasthenia Gravis (gMG) | Phase 1 |
| Next-generation complement inhibitors | Undisclosed autoimmune indications | Discovery |